Product Overview
Structure
Active ingredients:
Enterococcus faecium
Bifidobacterium longum
Excipients:
anhydrous dextrose 162.5 mg,
yeast fermentation 17.5 mg,
carob bean gum 12.5 mg,
magnesium stearate 2.5 mg,
lactulose 0.5 mg.
The composition of the capsule shell:
gelatin 48.0 mg,
titanium dioxide (0.96 mg) *,
magnesium stearate 0.5 mg,
methacrylic acid and methyl methacrylate copolymer [1: 1] 2.2 mg,
methacrylic acid and ethyl acrylate copolymer [1: 1] [30% dispersion] 7.7 mg,
talc 5.6 mg,
macrogol 6000 1.5 mg,
soybeans, purified oil 0.8 mg,
diacetylated glycerides 0.3 mg.
* the mass of titanium dioxide is included in the total weight of the gelatin capsule.
Enterococcus faecium
Bifidobacterium longum
Excipients:
anhydrous dextrose 162.5 mg,
yeast fermentation 17.5 mg,
carob bean gum 12.5 mg,
magnesium stearate 2.5 mg,
lactulose 0.5 mg.
The composition of the capsule shell:
gelatin 48.0 mg,
titanium dioxide (0.96 mg) *,
magnesium stearate 0.5 mg,
methacrylic acid and methyl methacrylate copolymer [1: 1] 2.2 mg,
methacrylic acid and ethyl acrylate copolymer [1: 1] [30% dispersion] 7.7 mg,
talc 5.6 mg,
macrogol 6000 1.5 mg,
soybeans, purified oil 0.8 mg,
diacetylated glycerides 0.3 mg.
* the mass of titanium dioxide is included in the total weight of the gelatin capsule.
pharmachologic effect
The strains of Enterococcus faecium and Bifidobacterium longum, which are part of the drug, are natural symbiotic bacteria that inhabit the gastrointestinal tract. The drug has a normalizing effect on the quantitative and qualitative composition of the intestinal microflora.
The action is due to both the direct direct effect of the components of the preparation (high antagonistic activity against pathogenic and conditionally pathogenic microorganisms), and indirectly - stimulation of the local intestinal immunity (activation of immunoglobulin A synthesis, induction of endogenous interferon synthesis).
Bifidobacterium longum has a high survival rate in the human intestines and a high growth rate. The inclusion in the preparation of apatogenic enterococcus Enterococcus faecium, which normally colonizes the small intestine, allows a positive effect on the condition and digestive functions of not only the large, but also the small intestine, especially in the presence of fermentative dyspepsia and flatulence.
The action is due to both the direct direct effect of the components of the preparation (high antagonistic activity against pathogenic and conditionally pathogenic microorganisms), and indirectly - stimulation of the local intestinal immunity (activation of immunoglobulin A synthesis, induction of endogenous interferon synthesis).
Bifidobacterium longum has a high survival rate in the human intestines and a high growth rate. The inclusion in the preparation of apatogenic enterococcus Enterococcus faecium, which normally colonizes the small intestine, allows a positive effect on the condition and digestive functions of not only the large, but also the small intestine, especially in the presence of fermentative dyspepsia and flatulence.
Indications
Diarrhea caused by acute and exacerbation of chronic gastroenteritis, rotavirus infection;
- in the treatment of acute intestinal infections;
- in the complex treatment of chronic diseases of the gastrointestinal tract, such as colitis, irritable bowel syndrome and other gastrointestinal disorders of functional origin;
- normalization of intestinal microflora, treatment and prevention of dysbiosis and maintaining the immune system in children over 2 years old and adults;
- lactose intolerance;
- as part of a comprehensive standard eradication therapy in patients with helicobacter infection.
- in the treatment of acute intestinal infections;
- in the complex treatment of chronic diseases of the gastrointestinal tract, such as colitis, irritable bowel syndrome and other gastrointestinal disorders of functional origin;
- normalization of intestinal microflora, treatment and prevention of dysbiosis and maintaining the immune system in children over 2 years old and adults;
- lactose intolerance;
- as part of a comprehensive standard eradication therapy in patients with helicobacter infection.
Contraindications
Individual hypersensitivity to the components of the drug.
How to take, course of administration and dosage
In acute diarrhea, the drug should be taken 1 capsule 4 times a day until stool normalizes. Then, the drug should be continued at a dose of 2-3 capsules per day until the symptoms disappear completely.
To normalize the intestinal microflora and support the immune system, the drug is prescribed in a dose of 2-3 capsules per day for 10-21 days.
Patients with lactose intolerance are recommended to take the drug 1 capsule 3 times a day.
When carrying out eradication therapy, Bifiform is prescribed 2 capsules 2 times a day for two weeks from the first day of eradication therapy.
For children from 2 years old, 1 capsule 2-3 times a day.
The duration of admission can be adjusted on the recommendation of a doctor.
When prescribing to children and patients who cannot swallow a whole capsule, it should be gently broken, carefully avoiding losses, pour the contents into a spoon and mix with a small amount of liquid.
If you have questions, please consult your doctor.
To normalize the intestinal microflora and support the immune system, the drug is prescribed in a dose of 2-3 capsules per day for 10-21 days.
Patients with lactose intolerance are recommended to take the drug 1 capsule 3 times a day.
When carrying out eradication therapy, Bifiform is prescribed 2 capsules 2 times a day for two weeks from the first day of eradication therapy.
For children from 2 years old, 1 capsule 2-3 times a day.
The duration of admission can be adjusted on the recommendation of a doctor.
When prescribing to children and patients who cannot swallow a whole capsule, it should be gently broken, carefully avoiding losses, pour the contents into a spoon and mix with a small amount of liquid.
If you have questions, please consult your doctor.
Description
Bifiform® - an effective drug for the treatment of dysbiosis!
Advantages of the preparation:
Studied bacteria: The composition of the preparation includes studied, safe and beneficial probiotic bacteria from the leading microbiological laboratory Christian Hansen (Denmark).
Two-layer protective shell: The Bifiform® capsule has a two-layer protective shell, due to which the entire complex of beneficial probiotic bacteria is delivered precisely to the intestine. Bacteria do not break down under the action of the acidic environment of the stomach and retain their beneficial properties when they enter the intestines.
Special nutrient medium for beneficial bacteria: Bifiform®, in addition to beneficial bacteria, contains a special nutrient medium for their nutrition, growth and reproduction.
Bifiform® Lactose Free
There is no connection with food intake.
Advantages of the preparation:
Studied bacteria: The composition of the preparation includes studied, safe and beneficial probiotic bacteria from the leading microbiological laboratory Christian Hansen (Denmark).
Two-layer protective shell: The Bifiform® capsule has a two-layer protective shell, due to which the entire complex of beneficial probiotic bacteria is delivered precisely to the intestine. Bacteria do not break down under the action of the acidic environment of the stomach and retain their beneficial properties when they enter the intestines.
Special nutrient medium for beneficial bacteria: Bifiform®, in addition to beneficial bacteria, contains a special nutrient medium for their nutrition, growth and reproduction.
Bifiform® Lactose Free
There is no connection with food intake.
